Predictive Value of the Differential Expression of the Urokinase Plasminogen Activation Axis in Radical Prostatectomy Patients

European Urology

Volumn 55, Issue 5, 2009, Pages 1124-1134

  Gupta, Amit ^a   Lotan, Yair ^a   Ashfaq, Raheela ^a   Roehrborn, Claus G ^a   Raj, Ganesh V ^a   Aragaki, Corinne C ^b   Montorsi, Francesco ^c   Shariat, Shahrokh F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Biochemical failure; Prostatic neoplasms; Radical Prostatectomy; Recurrence; Urokinase plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UROKINASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEMINAL VESICLE; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 62649132399     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.054     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Han M., Partin A.W., Pound C.R., Epstein J.I., and Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
3. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910-914
4. Duffy M.J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10 (2004) 39-49
5. Look M.P., van Putten W.L., Duffy M.J., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94 (2002) 116-128
6. Mulcahy H.E., Duffy M.J., Gibbons D., et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344 (1994) 583-584
7. Ohba K., Miyata Y., Kanda S., et al. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 174 (2005) 461-465
8. Sakakibara T., Hibi K., Koike M., et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 93 (2005) 799-803
9. Sakakibara T., Hibi K., Koike M., et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer. Cancer Sci 97 (2006) 395-399
10. Shariat S.F., Monoski M.A., Andrews B., et al. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology 61 (2003) 1053-1058
11. Janicke F., Prechtl A., Thomssen C., et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93 (2001) 913-920
12. Cozzi P.J., Wang J., Delprado W., et al. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 37 (2006) 1442-1451
13. Kirchheimer J.C., Pfluger H., Ritschl P., Hienert G., and Binder B.R. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 5 (1985) 344-355
14. Henson D.E., Hutter R.V., and Farrow G. Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. A publication of the cancer committee, College of American Pathologists. Task Force on the Examination of Specimens Removed From Patients With Prostate Cancer. Arch Pathol Lab Med 118 (1994) 779-783
15. Leventis A.K., Shariat S.F., Kattan M.W., et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19 (2001) 1030-1039
16. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
17. Lee A.K., and D'Amico A.V. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23 (2005) 8192-8197
18. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
19. Rabbani S.A., and Mazar A.P. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 10 (2001) 393-415 x
20. Sakakibara T., Hibi K., Kodera Y., et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin Cancer Res 10 (2004) 1375-1378
21. Kuhn W., Pache L., Schmalfeldt B., et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55 (1994) 401-409
22. McMahon G.A., Petitclerc E., Stefansson S., et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276 (2001) 33964-33968
23. Kwaan H.C., Wang J., Svoboda K., and Declerck P.J. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 82 (2000) 1702-1708
24. Liu G., Shuman M.A., and Cohen R.L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60 (1995) 501-506
25. Achbarou A., Kaiser S., Tremblay G., et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54 (1994) 2372-2377
26. Dondi D., Festuccia C., Piccolella M., Bologna M., and Motta M. GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncology Reports 15 (2006) 393-400
27. Rabbani S.A., Harakidas P., Davidson D.J., Henkin J., and Mazar A.P. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 63 (1995) 840-845
28. Van Veldhuizen P.J., Sadasivan R., Cherian R., and Wyatt A. Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci 312 (1996) 8-11
29. Miyake H., Hara I., Yamanaka K., et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39 (1999) 123-129
30. Piironen T., Haese A., Huland H., et al. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 52 (2006) 838-844
31. Shariat S.F., Roehrborn C.G., McConnell J.D., et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25 (2007) 349-355
32. Harbeck N., Kates R.E., Look M.P., et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62 (2002) 4617-4622
33. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499-1507
34. Berkenblit A., Matulonis U.A., Kroener J.F., et al. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 99 (2005) 50-57
35. Ertongur S., Lang S., Mack B., et al. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 110 (2004) 815-824
36. Setyono-Han B., Sturzebecher J., Schmalix W.A., et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 93 (2005) 779-786
37. Crowley C.W., Cohen R.L., Lucas B.K., et al. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A 90 (1993) 5021-5025